Literature DB >> 23393017

CUX1 in leukemia: dosage matters.

Jacqueline Boultwood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23393017     DOI： 10.1182/blood-2012-12-473421

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Authors:  Zubaidah M Ramdzan; Charles Vadnais; Ranjana Pal; Guillaume Vandal; Chantal Cadieux; Lam Leduy; Sayeh Davoudi; Laura Hulea; Lu Yao; Anthony N Karnezis; Marilène Paquet; David Dankort; Alain Nepveu
Journal:  PLoS Biol       Date:  2014-03-11       Impact factor: 8.029

2.  Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor.

Authors:  Waner Wu; Na Xu; Xuan Zhou; Liang Liu; Yaxian Tan; Jie Luo; Jixian Huang; Jiayue Qin; Juan Wang; Zhimin Li; Changxin Yin; Lingling Zhou; Xiaoli Liu
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

Review 3.  Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy.

Authors:  Xiaonan Zhang; Tobias Sjöblom
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-13

4.  CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation.

Authors:  Heidi Griesmann; Sebastian Mühl; Jan Riedel; Katharina Theuerkorn; Bence Sipos; Irene Esposito; Gregory B Vanden Heuvel; Patrick Michl
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.